Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
258 results about "Human epidermal growth factor" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Human Epidermal Growth Factor (EGF) Description. Epidermal Growth Factor (EGF) is a polypeptide growth factor which stimulates the proliferation of a wide range of epidermal and epithelial cells. Recombinant human Epidermal Growth Factor (EGF) is a 6,200 Da protein containing 53 amino acid residues.
Whitening cosmetic product, preparation method and application thereof
ActiveCN101816620AGood whitening effectFor long-term storageCosmetic preparationsToilet preparationsVitamin CSide effect
The invention discloses a whitening cosmetic product, a preparation method and application thereof. The whitening cosmetic product comprises the components in percentage by mass: 0.00001to 0.001 percent of recombined human angiogenin, 0.00001 to 0.001 percent of metallothionein, 0.00001 to 0.001 percent of human epidermal growth factor, 0.00001to 0.001 percent of IL-1RA, 0.1 to 0.5 percent of superoxide dismutase, 0.1 to 0.5 percent of low molecular liquaemin, 1 to 5 percent of arbutin, 5 to 25 percent of stabilizer, 0.02 to 0.3 percent of hyaluronic acid, 0.5 to 5 percent of methylpropanediol, 0.5 to 3.5 percent of lactobacillus / mung bean fermentation liquid, 0.5 to 5 percent of dissolved protease, 0.5 to 8 percent of vitamin C sodium phosphate, 0.3 to 0.7 percent of 1,2-hexanediol or 1,2-capryl glycol, 1 percent to 5 percent of oat Beta-glucan, 1 to 5 percent of soy isoflavone and the balance of water. The whitening cosmetic product can be preserved for a long time, has no side effect on skin and is suitable for long term use.
Owner:广州泰润合投资有限公司
Serum-free culture medium for mesenchymal stem cells
ActiveCN102433302AGood growthFast growthSkeletal/connective tissue cellsINSULIN HUMANPancreatic hormone
The invention discloses a serum-free culture medium for mesenchymal stem cells. The serum-free culture medium for the mesenchymal stem cells comprises the following ingredients: fibronectin at the final concentration of 25mu g / ml, basic fibroblast growth factors at the final concentration of 10ng / ml, human epidermal growth factors at the final concentration of 15ng / ml, recombinant human insulin at the final concentration of 1mg / ml, human transferrin at the final concentration of 0.55mg / ml, human blood albumin in a volume ratio of 5 percent, sodium selenite at the final concentration of 0.67mug / ml, L-carnitine at the final concentration of 5mM and resveratrol at the final concentration of 30mu M. When the mesenchymal stem cells are cultured by the serum-free culture medium for the mesenchymal stem cells, animal-derived serum is not contained, so infection risks can be controlled; the L-carnitine and the resveratrol which are added into the serum-free culture medium for the mesenchymalstem cells can effectively improve the growth state of the mesenchymal stem cells; and the growth speed of the mesenchymal stem cells is remarkably improved, and the biological characteristics of themesenchymal stem cells are kept unchanged.
Owner:CHENGDU QINGKE BIOTECH
Bispecific antibodies against her2
InactiveUS20140170148A1High HER downmodulationInhibition is effectiveAnimal cellsRadioactive preparation carriersEpitopeBispecific antibody
Bispecific antibodies which comprise antigen-binding regions binding to two different epitopes of human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and methods of preparing and using the antibodies are also disclosed.
Owner:GENMAB AS
Nucleic acid for coding chimeric antigen receptor protein and T lymphocyte for expression of chimeric antigen receptor protein
InactiveCN104087607AHigh transduction efficiencyEffective immunotherapyAntibody mimetics/scaffoldsBlood/immune system cellsAntigen receptorEpitope
The invention discloses a nucleic acid for coding a chimeric antigen receptor protein expressed on the surface of the human T lymphocyte. The chimeric antigen receptor protein comprises an extracellular binding domain, a transmembrane domain and an intracellular signal domain, and the extracellular binding domain, the transmembrane domain and the intracellular signal domain are orderly connected. The extracellular binding domain comprises a single-chain antibody scFv (epidermal growth factor receptor EGFR) for specific recognition of 287th-302th amino acid epitopes of EGFR.
Owner:CRAGE MEDICAL CO LTD
Determining an expression status of human epidermal growth factor receptor 2 (HER2) in a biological sample
A method for determining an expression of human epidermal growth factor receptor 2 (HER2) of a subject. The method includes providing a sample from the subject; measuring one of (i) amounts of two or more proteins in the sample, each protein having a molecular weight substantially equal to 4740, 8404, 8419, 8435, 8450, 8455, 8465, 8570, 8607 or 8626 atomic mass units, and (ii) amounts of at least one of human cystein-rich intestinal protein 1 (CRIP1), one or more variants of the human cystein-rich intestinal protein 1 (CRIP1 variants), and proteolytic digestion products thereof in the sample; and comparing the amounts of the proteins to control amounts, which control amounts are determinative of the expression of the human epidermal growth factor receptor 2.
Owner:BRUKER DALTONIK GMBH & CO KG
Novel diabody-type bispecific antibody
InactiveUS20060210564A1Increase productionBacteriaPeptide/protein ingredientsChemical synthesisGenetic engineering
The purpose of the present invention is to provide a diabody-type bispecific antibody, which is characterized by having low immunogenicity and high infiltrating activity into tumor tissues, and by being easily mass-produced at a low cost with use of microorganisms, and by being easily altered in function by means of genetic engineering. The diabody-type bispecific antibody shows a more remarkable effect than the conventional diabody-type bispecific antibodies and chemically synthesized bispecific antibodies even in a very low concentration and in the absence of the super antigen. The present invention is related to a diabody-type bispecific antibody, having a first specificity to a human epidermal growth factor (EGF) receptor and a second specificity to a surface antigen expressed by a cell having phagocytosis or cytotoxic activity, a single-chain polypeptide constituting the antibody or each region contained therein, a nucleic acid encoding the polypeptide, a replicable cloning vector or expression vector comprising the nucleic acid, a host cell transformed with the vector, and a pharmaceutical preparation comprising thereof.
Owner:TOHOKU TECHNO ARCH CO LTD
Escherichia expression system of secretory expression recombinant human epidermal growth factor
This invention includes signal peptide gene phoAspL10, expression plasmid pBL10EGF, host cell of bacillus coli BL21 (DE3) inverted by expression plasmid pBL10EGF, engineering strain BE-2 screened from the host cell and preparation method of rhEGF. The strain BE-2 can excrete and express rhEGF directly into culture after fermentation and the quantity is 384mg / l.The purity is more than 95% and specific activity more than 1.0*106IU / mg protein. The product rhEGF reserves crude space configuration and shows high biological activity.
Owner:SHANGHAI HAOHAI BIOLOGICAL TECH
Diabody-type bispecific antibody
Owner:TOHOKU TECHNO ARCH CO LTD
Monoclonal antibodies against her2
ActiveUS20130189271A1Improve efficiencyImproved internalizationAnimal cellsImmunoglobulins against cell receptors/antigens/surface-determinantsMonoclonal antibodyHuman Epidermal Growth Factor Receptor 2
Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related anti-body-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
Owner:GENMAB AS
Bispecific HER2 and HER3 Antigen Binding Constructs
InactiveUS20160083480A1Ultrasonic/sonic/infrasonic diagnosticsVaccination/ovulation diagnosticsHuman epidermal growth factor receptorExtracellular Structure
Described herein are isolated bi-specific antigen binding constructs, e.g., antibodies. The bi-specific antigen binding constructs include two antigen binding polypeptide constructs, e.g., a Fab and an scFv. The first antigen-binding polypeptide construct monovalently and specifically binds to extracellular domain 4 (ECD4) of HER2 (human epidermal growth factor receptor 2); the second antigen-binding polypeptide construct monovalently and specifically binds to an extracellular domain (ECD) of HER3 (human epidermal growth factor receptor 3). One antigen binding polypeptide construct is a Fab format and the other antigen binding polypeptide construct is an scFv format. The bi-specific antigen binding constructs includes an Fc having two Fc polypeptides each having a CH3 domain for dimerization. Each Fc polypeptide is linked to the C-terminus of one of the antigen binding polypeptide constructs with or without a linker.
Owner:ZYMEWORKS INC
Bispecifc antibodies against HER2
Bispecific antibodies which comprise antigen-binding regions binding to two different epitopes of human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and methods of preparing and using the antibodies are also disclosed.
Owner:健玛保
Method for preparing dissolvable high activity recombinant human epidermal growth factor
ActiveCN101353659AHigh activityHigh purityPeptide preparation methodsFermentationEscherichia coliChemical synthesis
The invention relates to the technical field of gene recombination, in particular to a method for preparing soluble and high-activity recombinant human epidermal growth factor; the invention solves the problems that the human epidermal growth factor which is obtained by using the chemical synthesis method and the biological extraction method which have different self-defects respectively and by using the gene recombination method has lower purify and low yield and activity, and comprises the following steps of: constructing the gene cloning of the human epidermal growth factor, replacing codons which are not beneficial to be expressed by Escherichia coli to obtain optimized gene sequence, adding molecular chaperone of PDI to help target gene to be expressed effectively in Escherichia coli, and embedding HIS label and enzyme cutting site of protein in the sequence to help the target gene to be purified effectively, and the identification of biological activity; the obtained human epidermal growth factor has high purify, high yield, high activity, low cost, simple production technique and stable product quality; the product can be used for manufacturing drugs or articles for beauty and cosmetics and is beneficial to be promoted to the public.
Owner:SHANXI JINBO BIO PHARMA CO LTD
Serum-free culture medium, preparation method thereof and culture method of mesenchymal stem cells
ActiveCN110923196AImprove proliferative abilityImprove performanceCulture processSkeletal/connective tissue cellsPolyvinyl alcoholHydrocortisone
Owner:GUANGZHOU SALIAI STEMCELL SCI & TECH CO LTD
Polypeptide for specifically targeting human epidermal growth factor receptor 2 (HER2) protein
ActiveCN104130315AIncrease contentHigh purityRadioactive preparation carriersDepsipeptidesChemical synthesisCancer cell
The invention relates to a polypeptide for specifically targeting a human epidermal growth factor receptor 2 (HER2) protein. The polypeptide is shown in the following general formula 1 of X1X2X3X4X5X6X7RX8YWX9X10X11X12X13X14X15X16X17RX18X19X20X21YX22. The invention also relates to a nucleotide sequence for coding the polypeptide, an expression vector for expressing the polypeptide and a host cell. The invention also relates to the polypeptide and its bivalent or multivalent, a pharmaceutical composition prepared from the polypeptide or its bivalent or multivalent as a targeting polypeptide, a preparation for killing cancer cells and a developing agent, and a use of the polypeptide and its bivalent or multivalent. The polypeptide has HER2 positive cell targeting effects and strong selectivity. The polypeptide can be prepared by a chemical synthesis method and has the advantages of high purity, small molecular weight, strong singularity, no immunogenicity, safety and reliability.
Owner:THE NAT CENT FOR NANOSCI & TECH NCNST OF CHINA
Serum-free cryoprotectant, and application thereof in cryopreservation of mesenchymal stem cells
ActiveCN107494517AImprove survival rateIncreased clinical allergen riskDead animal preservationUmbilical cordResuscitation
A serum-free cryoprotectant includes: 8-15 v / v% of DMSO, 85-92 v / v% of a DMEM basic culture medium, and a nutritional additive. The nutritional additive includes: fibroblast growth factors, insulin, growth hormone, transferrin, bone morphogenetic protein 4, glutamine, sodium pyruvate, beta-mercaptoethanol, human epidermal growth factor, sodium selenite, and various amino acids and vitamins. The cryoprotectant is free of animal sourced serum and avoids pollution and risk of allergen, and has better clinical safety. The serum-free cryoprotectant is suitable for cryopreservation of human placenta sourced, umbilical cord sourced and cord blood sourced mesenchymal stem cells; compared with common serum cryoprotectants, perinatal mesenchymal stem cells preserved in the cryoprotectant have high cell survival rate after resuscitation, have excellent adherence growth status and maintain biological characters well.
Owner:章毅 +7
Cell culture medium and application thereof in culturing primary human tumor cells
The invention discloses a cell culture medium. The raw material formula of the cell culture medium comprises 33.33ml of DMEM / High Glucose (DMEM high-glucose culture medium), 66.67ml of HAM'S / F-12 culture medium, 3-5mg / mL of plant-origin recombinant human serum albumin, 100U / ml of penicillin, 100 micrograms / milliliter of streptomycin, 2.5 micrograms / milliliter of amphotericin B, 0.2-0.5 micrograms / milliliter of hydrocortisone, 3-6 micrograms / milliliter of insulin, 6-10ng / ml of cholera toxin B, 9-12ng / ml of human epidermal growth factor EGF, 22-25 micrograms / milliliter of adenine, and 7-9 micromoles / liter of Y-27632. The cell culture medium can be used for culturing primary human tumor cells or tumor stem cells. The cell culture medium is improved; when the cell culture medium is applied to culturing the primary human tumor cells or the tumor stem cells, the cell culture medium is capable of better accelerating the growth of the primary tumor cells and obtaining the human tumor stem cells of a higher ratio.
Owner:山东大学附属千佛山医院
Human epidermal growth factor nanoliposome and its preparation method
InactiveCN102247300AHigh molecular weightHigh affinityCosmetic preparationsToilet preparationsCholesterolCuticle
The invention discloses a human epidermal growth factor nanoliposome, which contains liposome microcapsules and human epidermal growth factor wrapped in the liposome microcapsules, wherein the mass ratio of the human epidermal growth factor to the liposome microcapsules ranges from 1: 50 to 1: 200. The invention also discloses a method for preparing the human epidermal growth factor nanoliposome. Phosphatide and cholesterol are adopted as the main membrane materials, whose biomembrane-like structures are similar to the skin structure and have good transdermal permeability, and are easier to prepare a lipid carrier with a uniform particles size and high entrapment rate by a preparation technology. According to the invention, human epidermal growth factor (hEGF) is prepared into the nanoliposome. As a raw material, the nanoliposome supplemented by other biologically-active substances such as hyaluronic acid is prepared by a corresponding preparation technology into aqua, cream and emulsion skin care products, so as to rapidly repair damaged skin, repair and remove wrinkles, nurse after sunscreen and radiation examination, nurse sensitive skin, and remove and repair various scars.
Owner:TIANJIN TIANSHI BIOLOGICAL DEV +2
Double-functional fusion protein based on antibacterial peptide, preparation method and applicaitoin thereof
InactiveCN101698682ASmall molecular weightHigh molecular weightPeptide/protein ingredientsMicroorganism based processesDiseaseLink protein
The invention discloses a double-functional fusion protein based on an antibacterial peptide, a preparation method and an application thereof. The double-functional fusion protein based on the antibacterial peptide is a fusion protein based on a cecropins B protein sequence and a human epidermal growth factor; the linking protein is especially designed to be a locus which can be identified by thrombin; and a purified His tag is constructed on the fusion protein. In the invention, the biological preparation for the fusion protein is realized by using a prokaryotic expression system and the purified fusion protein is obtained. A bacteriostasis test and a verification for realizing live animals are performed by the purified fusion protein to indicate that the fusion protein can be applied to preparing a medicine for treating epidermal wound, can be applied to diseases such as epidermal wound, abrade, burn and scald, etc., and can prevent wound from being infected.
Owner:MICROBIOLOGY INST OF SHAANXI
Cervical mucosa inducing gel
InactiveCN101690802ASuspension is effectiveNo side effectsOrganic active ingredientsPeptide/protein ingredientsTriclosanAfter treatment
The invention relates to a gel which can improve vaginal microenvironment and restore vaginal microdamage and is suitable for treatment on various kinds of vaginitis and cervicitis caused by vaginal microecological disturbance and vaginal microdamage, auxiliary treatment on vaginitis and cervicitis after clinical treatment, and treatment on cervical erosion, in particular to a cervical mucosa inducing gel which comprises carbomer, triclosan and human epidermal growth factors, wherein the concentration of the carbomer is 3%-5%, the concentration of the triclosan is 0.1%-0.6%, and the concentration of the human epidermal growth factors is 1 / 100000-1 / 10000. The cervical mucosa inducing gel can effectively improve the vaginal cleanness and increase the lactobacillus quantity to further reduce the vaginal pH value, has obvious effect on restoring cervical erosion, and can be used for auxiliary treatment on vaginitis and cervicitis after treatment.
Owner:杨霞
Applications of human growth hormone and human epidermal growth factor combination in beauty treatment
ActiveCN101249043AGood cosmetic effectPromote repairCosmetic preparationsToilet preparationsSomatotropic hormoneBiological macromolecule
The invention discloses the use of a composition comprising human growth hormone and human epidermal growth factor in cosmetics and provides a production process thereof. The invention uses human growth hormone in cosmetics together with human epidermal growth factor by using biotechnology. The human growth hormone and the human epidermal growth factor has synergistic effects in supplementing bioactive factors for promoting epidermal cell metabolism and proliferation, thereby basically improving the physiological status of skin, promoting repairing and metabolism of epidermal tissues, promoting extracellular synthesis of biomacromolecules such as hyaluronic acid and glycoprotein, promoting skin tendering and rejuvenation, relieving color spots, reducing wrinkles, and resisting aging. The inventive composition has remarkably cosmetic effect and has the advantages of good safety and reliability, and no adverse side effects.
Owner:吉林省盛赛医药实业有限公司
Selective medium of liver stem cells, method for selectively separating and amplifying liver stem cells as well as medicinal composition for treating diabetes
InactiveCN101851605AIncreased cost securityImprove securityMetabolism disorderPharmaceutical delivery mechanismCuticleFactor ii
The invention provides a selective medium of liver stem cells. The selective medium comprises a liquid-based medium, and the volume of the liquid-based medium is used as a standard. The selective medium also comprises 1-20vol% of fetal calf serum, 5-100ng / mL of human epidermal growth factors and 5-100ng / mL of basic fibroblast growth factors. The invention also provides a method for selectively separating and amplifying liver stem cells from in vitro tissues by using the selective medium. The invention also provides a medicinal composition for treating diabetes, which contains the liver stem cells prepared by using the method. The method using the selective medium can separate and amplify liver stem cells in high efficiency and in a large amount, and the liver stem cells subcultured and amplified through 10 generations still maintain the same properties with the primary liver stem cells. The medicinal composition for treating diabetes can restore damaged islet beta cells of a person with diabetes, and can eliminate insulin resistance.
Owner:北京弘润天源基因生物技术有限公司
Method for preparing nanometer bionic slow release biomedical dressing by electrostatic spinning
InactiveCN103394119ALow priceGood biocompatibilityFilament/thread formingAbsorbent padsSpinningBiology
The invention provides a nanometer bionic slow release biomedical dressing and a preparation method thereof. The nanometer bionic slow release fibrous membrane dressing is applied to providing a good microenvironment to union of wounds and promoting hemostasis, analgesia and antibiosis. The stoste of the nanometer bionic slow release biomedical dressing is aqueous liquor containing silk fibroin, human epidermal growth factors and fibroblast growth factors, and the pH value is 5-8, wherein the mass percentage concentration of silk fibroin is 2-30% and total concentration of the human epidermal growth factors and the fibroblast growth factors is 0-200ppm; or chitosan with the mass percentage concentration of 1-10% replaces the silk fibroin; the electrostatic spinning technology is adopted, so that the stoste of the nanometer bionic slow release biomedical dressing forms a spraying jet which is sprayed to a collector so as to obtain the nanometer bionic slow release biomedical dressing.
Owner:FOURTH MILITARY MEDICAL UNIVERSITY
Serum-free medium of human amniotic epithelial stem cell and culture method thereof
ActiveCN106834218AOvercoming difficulties in obtaining materialsOvercome limitationsCell dissociation methodsCulture processCuticleSingle cell suspension
The invention relates to a serum-free medium of a human amniotic epithelial stem cell and a culture method thereof. The serum-free medium is formed by adding a human epidermal growth factor, human transferring, human insulin, sodium selenite, alanyl-L-glutamine dipeptide, alanine, asparaginate, aspartic acid, glutamic acid, glycine, proline and serine to a DMEM / F12 basic medium. The culture method comprises the steps of digesting 2.5g / L of trypsin for a human amniotic membrane, obtaining the human amniotic epithelial stem cell and filtering to prepare a single cell suspension; putting the human amniotic epithelial stem cell into a CO2 incubator of which the saturated humidity and the volume fraction are 5% at 37 DEG C through the serum-free medium under a serum-free condition and achieving growth and amplification of the amniotic epithelial stem cell through liquid exchange and subculture under the serum-free culture condition, the serum-free medium has the characteristics of stem cells, and is free of other animal sources, wide in source and free of ethical restriction.
Owner:沈阳艾米奥生物工程技术研发中心有限公司
Method for producing human epidermal growth factor in large volume from yeast
ActiveUS20130323785A1Easily produced excessivelyDecrease productivityFungiFungi based processesHigh concentrationYeast
The present invention relates to a method for producing hEGF (human epidermal growth factor) which has the same activity as the wild form, in high concentration and with a high degree of purity. More specifically, the invention relates to an hEGF expression vector comprising a nucleic acid sequence coding for the polypeptide of sequence number 14; a host cell in which the expression vector has been genetically transformed; and a method for producing hEGF, comprising a step in which the expression vector is created and is genetically transformed in yeast from which the KEX1 gene is lacking. Using the method of the present invention, it is possible to produce a large volume of human derived EGF which has the same size and activity as human derived EGF, and this EGF can be used in various ways such as in medicine and cosmetics.
Owner:KOREA RES INST OF BIOSCI & BIOTECH
Ligand oligopeptide specific combining human epidermal growth factor receptor EGFR
InactiveCN1676166ATo achieve the purpose of targeted therapy for tumorsGenetic material ingredientsPeptidesExogenous DNAHuman epidermal growth factor receptor
The present invention provides a gene transfer system mediated by epidermal growth factor receptor (EGFR). It comprises (a) ligand oligopeptide specifically combined in EGFR, (b) polycation polypeptide or protein and optional (c) endocytic corpuscular release oligopeptide and (d) exogenous DNA. The described gene transfer system can effectively make the exogenous gene be target-introduced into the tumor cell expressing EGFR in vivo and in video so as to inhibit the growth of tumor.
Owner:REGENEX PHARMA LTD
Monoclonal antibodies against her2 epitope
ActiveUS20130171148A1Promote cell proliferationHighly effectiveImmunoglobulins against cell receptors/antigens/surface-determinantsFermentationEpitopeMonoclonal antibody
Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
Owner:GENMAB AS
Primer and method for detecting human EGFR gene mutation
ActiveCN104131091AMicrobiological testing/measurementDNA/RNA fragmentationGrowth Factor GeneEGFR Gene Mutation
The invention belongs to the field of biotechnology, especially the detection of gene mutation. More specifically, the invention discloses 9 groups of primers for detection of 41 mutation of a human epidermal growth factor EGFR gene and a detection method by using the primers.
Owner:艾吉泰康(嘉兴)生物科技有限公司
Monoclonal antibodies against HER2 epitope
ActiveUS9714294B2Promote proliferationHighly effectiveImmunoglobulins against cell receptors/antigens/surface-determinantsFermentationMonoclonal antibodyHuman Epidermal Growth Factor Receptor 2
Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
Owner:GENMAB AS
Improved culture medium for neonatal pig islet cells and use method of same
ActiveCN103695367AIncrease enzyme activityPromote decompositionVertebrate cellsArtificial cell constructsInsulin-like growth factorPenicillin
Owner:HUNAN XENO LIFE SCI
Double function epidermal growth factor and its preparation method and uses
InactiveCN1865286AHigh affinityStrong specificityCosmetic preparationsPeptide/protein ingredientsFiberCuticle
The invention discloses a human epiderm growth factor with 53 amino acids to form cellar factor, which is characterized by the following: forming molecular bridge of four amino acids to connect human epiderm growth factor and collagen protein combination region; producing the fusion protein with high biological activity and high specific collagen combination activity. The double-functional epiderm growth factor can restore human internal and external wound, which can be applied in the cosmetics.
Owner:北京上地新世纪生物医药研究所有限公司
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com